Primary screening of candidate RNA biomarkers for diagnostics of prostate cancer

Resumo

Applicability of prostate cancer candidate RNA biomarkers screening in plasma and urine obtained by minimally invasive or noninvasive methods has been demonstrated. In patients with benign prostatic hyperplasia (BPH) significant amounts of RNAs known in the literature as biomarkers associated with prostate cancer have been detected in plasma and urine samples. Detectable amounts of the markers depended on the methods used for transcriptome profiling. Detection of known RNA biomarkers associated with prostate cancer in urine and plasma samples by the RNA-seq method shows its applicability for the search of new RNA biomarkers for minimally invasive diagnostics. However, the fact of the presence of known prostate cancer RNA biomarkers in samples from BPH patients suggests their insufficient specificity and indicates a clear need for further research in this field.